Therapeutic Benefit of Top-Selling Oncology Drugs in Medicare
This cohort study examines whether international health technology assessment reviews may identify oncology drugs that are suitable for aggressive price negotiation.
Authors
- Georg Hahn (ORCID: https://orcid.org/0000-0001-6008-2720)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Alexander C. Egilman (ORCID: https://orcid.org/0000-0002-5343-4908)
- Stephanie Wang (ORCID: https://orcid.org/0000-0002-9244-2492)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Harvard College Observatory (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.3323
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Kaiser Permanente
- Arnold Ventures